Innexus Biotechnology Inc. (IXS) Announces Collaboration Focused On Developing Novel Antiviral Antibodies
10/3/2006 11:44:29 AM
VANCOUVER, British Columbia--(BUSINESS WIRE)--InNexus Biotechnology (TSX VENTURE:IXS) (OTCBB:IXSBF) today announced that it has entered into a technology collaboration agreement to evaluate the use of InNexus’ SuperAntibody Technology in combination with an antibody for the treatment of certain viral infections. InNexus will work with antibody therapeutic company EvoGenix Limited (ASX:EGX), which is developing an improved version of the antiviral drug for clinical testing.
comments powered by